TP53 and neoplasm: Among individuals fulfilling Chompret A criteria, there were no differences in multiple tumours occurrence, familial appearance, rare tumour type, or early-onset breast tumour development between LFS (TP53 P/LP carriers) and phenotypic LFS patients (TP53 wild-type genotype).